Status:

RECRUITING

: Vascular Function in Health and Disease

Lead Sponsor:

Russell Richardson

Conditions:

Chronic Obstructive Pulmonary Disease

Pulmonary Artery Hypertension

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

Many control mechanisms exist which successfully match the supply of blood with the metabolic demand of various tissues under wide-ranging conditions. One primary regulator of vasomotion and thus perf...

Detailed Description

Angiotensin-II (ANG-II) is the end-product of the renin-angiotensin cascade, and acts as a potent endogenous vasoconstrictor through binding to the angiotensin receptor (AT1) on arteriolar vascular sm...

Eligibility Criteria

Inclusion Criteria:

  • Healthy Young Volunteers: 18-30 years of age with no diseases or conditions that would affect their participation in the study
  • Healthy Older Controls: volunteers 65 years of age or older with no diseases or conditions that would affect their participation in the study
  • Coronary Angiography subjects: patients undergoing routine coronary angiography
  • Chronic Obstructive Pulmonary Disease subjects: patients diagnosed with mild to moderate COPD
  • Pulmonary Arterial Hypertension subjects: patients with idiopathic or heritable Group 1 pulmonary arterial hypertension
  • Heart Failure subjects: patients with Class I, II or III New York Heart Association symptoms of Heart Failure
  • Hypertension subjects: patients diagnosed with chronic high blood pressure

Exclusion Criteria:

  • Severe COPD (use of supplemental oxygen, or have a one-second forced expiratory volume of less than 30% predicted)
  • History of myocardial infarction
  • History of percutaneous coronary revascularization
  • History of coronary artery bypass grafting
  • Unstable angina pectoris
  • History of variant angina
  • Ejection fraction < 50%
  • Significant renal disease (Glomerular Filtration Rate < 50 mL/min/1.73m2)
  • Subjects whose medical care or safety may be at risk from undergoing a Magnetic Resonance Imaging examination (e.g. pacemaker, metal implants, certain types of heart valves)
  • Subject is pregnant
  • Subject has physical ailments (other than COPD, PAH, HF, or hypertension) that would prevent them from study participation in the judgment of the investigator

Key Trial Info

Start Date :

September 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

August 1 2026

Estimated Enrollment :

420 Patients enrolled

Trial Details

Trial ID

NCT02966665

Start Date

September 1 2008

End Date

August 1 2026

Last Update

September 26 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

George E Wahlen VA Medical Center

Salt Lake City, Utah, United States, 84132